e-learning
resources
Vienna 2009
Monday, 14.09.2009
Drug effects in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Influence of statin therapy on exacerbation frequency in patients with COPD
S. O. Tandogdu, E. Eryuksel, S. Karakurt, H. Senol, T. Celikel (Istanbul, Turkey)
Source:
Annual Congress 2009 - Drug effects in COPD
Session:
Drug effects in COPD
Session type:
Thematic Poster Session
Number:
2009
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. O. Tandogdu, E. Eryuksel, S. Karakurt, H. Senol, T. Celikel (Istanbul, Turkey). Influence of statin therapy on exacerbation frequency in patients with COPD. Eur Respir J 2009; 34: Suppl. 53, 2009
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Related content which might interest you:
Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline
Source: International Congress 2018 – COPD management
Year: 2018
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD
Source: Annual Congress 2011 - COPD management
Year: 2011
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019
Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019
Year: 2019
Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Effect of asthma and asthma medication on the prognosis of patients with COVID-19
Source: Eur Respir J, 57 (3) 2002226; 10.1183/13993003.02226-2020
Year: 2021
Effect of roflumilast in patients with severe COPD and a history of hospitalisation
Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017
Year: 2017
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations
Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019
Year: 2019
Duration of systemic corticosteroids treatment in COPD exacerbations
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Variability in exacerbation frequency in COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 264s
Year: 2002
Phenotype-based therapy of COPD: Effect on the rate of COPD exacerbations
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
Effect of azithromycin treatment on inflammation in COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015
Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD
Source: ERJ Open Res, 4 (3) 00087-2018; 10.1183/23120541.00087-2018
Year: 2018
Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 212s
Year: 2002
Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses
Source: International Congress 2017 – COPD management
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept